Country for PR: United Kingdom
Contributor: PR Newswire Europe
Thursday, November 25 2021 - 18:45
Innovative Euro 250,000 Parenteral Nutrition Research Grant Awarded by Fresenius Kabi
BAD HOMBURG, Germany, Nov. 25, 2021 /PRNewswire-AsiaNet/--

Fresenius Kabi was delighted to announce the winner of their innovative 
JUMPstart education program and research grant on September 10, 2021. JUMPstart 
is an initiative that aims to nurture research in the field of parenteral 
nutrition through the mentoring, education and networking of clinicians and 
researchers. The grant is awarded to help to advance novel, community-led 
research in parenteral nutrition, to make a difference for critically ill 

This year's winner is Professor Stefan Schaller M.D. of Charite – 
Universitatsmedizin Berlin, Germany, for his proposal entitled "Improved muscle 
metabolism by combination of muscle activation and protein substitution." This 
cutting-edge study aims to explore the effect of protein substitution before 
and after early, goal-directed mobilization in the acute phase of critical 
illness. The announcement was made at the European Society for Clinical 
Nutrition and Metabolism (ESPEN) Congress.

During the virtual awards ceremony, Professor Schaller said: "After working on 
this research proposal for a long time, me and my research team are thrilled to 
be able to now conduct the study, and I am very thankful to the generous grant 
from Fresenius Kabi. I am very optimistic that this trial will have an impact 
on nutrition therapy in critical care."

Professor Schaller took part in the program alongside 18 other participants 
from around the world, including representation from Africa, Asia, Australia, 
Europe, New Zealand, and North and South America. After four training sessions, 
participants presented their research proposals to an independent international 
scientific committee, which consisted of five field-leading experts: Professor 
Mette Berger, Switzerland; Professor Olav Rooyackers, Sweden; Professor Tim 
Friede, Germany; Professor Robert Martindale, USA; and Professor Ho-Seong Han, 
South Korea. The committee was impressed by the high-quality level of all 
proposals, and this made picking a winner extremely challenging.

Dr. Jos Simons, Executive Vice President at Fresenius Kabi, commented: "We are 
absolutely delighted to be able to award this research grant to Professor 
Schaller. Both the scientific committee and Fresenius Kabi were astounded by 
his proposal and the positive impact it will have on clinical practice. We are 
very excited for Professor Schaller to start this clinical study."

This is the second JUMPstart research grant worth Euro 250,000. The first 
program of 19 participants completed in 2019, with the grant awarded to 
dietician Lizl Veldsman, Tygerberg Academic Hospital in Cape Town, South 

With the JUMPstart education program and research grant, Fresenius Kabi 
supports the next generation of clinical experts who will contribute to 
advancement in nutrition therapy in critically ill patients. 

Fresenius Kabi is a global healthcare company that specializes in lifesaving 
medicines and technologies for infusion, transfusion and clinical nutrition. 
The company's products and services are used to help care for critically and 
chronically ill patients. Fresenius Kabi's product portfolio comprises a 
comprehensive range of I.V. generic drugs, infusion therapies and clinical 
nutrition products as well as the devices for administering these products. In 
the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and 
oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. 
Within transfusion medicine and cell therapies, Fresenius Kabi offers products 
for collection of blood components and extracorporeal therapies.

With its corporate philosophy of "caring for life", the company is committed to 
putting essential medicines and technologies in the hands of people who help 
patients and finding the best answers to the challenges they face.

Fresenius Kabi employs around 40,500 people worldwide. In 2020, the company 
reported sales of around Euro 7.0 billion. Fresenius Kabi AG is a wholly owned 
subsidiary of the Fresenius SE & Co. KGaA healthcare group.

For more information, please visit 

This release contains forward-looking statements that are subject to various 
risks and uncertainties. Future results could differ materially from those 
described in these forward-looking statements due to certain factors, e.g. 
changes in business, economic and competitive conditions, regulatory reforms, 
results of clinical trials, foreign exchange rate fluctuations, uncertainties 
in litigation or investigative proceedings, and the availability of financing. 
Fresenius Kabi does not undertake any responsibility to update the 
forward-looking statements in this release.

Management Board: Michael Sen (Chairman), Marc Crouton, John Ducker, Dr. Oskar 
Haszonits, Dr. Christian Hauer, Dr. Michael Schonhofen, Gerrit Steen
Chairman of the Supervisory Board: Stephan Sturm
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg - HRB 11654

Contact: Emese Kamp 
         PINK CARROTS Communications GmbH 
         Phone: +49-69-4272614-141 

Photo - 
Logo  -
Source:  Fresenius Kabi